Cancer Education and Research Institute
United Nations, UNIATF Award 2019 Recipient
  • Home
    • About us
    • Annual Reports and Media Kit
    • News Room >
      • Press Releases 2019
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • TURKCE
    • Kanser videolarimizi izle
    • Kanser makalelerimizi oku
    • JSCR-Turkce
    • CERI Kisisellestirilmis Hasta Programi
    • Bağış Yap
  • Deutsch
    • Lernen Sie die Gründerin kennen
    • Unsere Krebs Videos ansehen
    • Unsere Krebs Artikel lesen
    • JSCR-Deutsch
    • Unsere Publikationen
    • CERI Personalisierter Patientenprogramm
  • MULTI-LANGUAGE CANCER BLOG
  • Patient Education
    • All about cancer
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Our Publications >
      • Read CERI Articles
    • Cancer Types-Education
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
    • CERI Personalized Patient Program
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Board Member Application
  • Contact us

CERI Research Laboratory Launch Fundraiser - by and for the public

9/4/2019

0 Comments

 
Tweet
We are thrilled to announce that we are now launching our CERI Cancer Research Laboratory! 
And the best of all - YOU will be a part of it! 
With our publicly funded cancer research laboratory, YOU will be directly a part of the success and achievement of our mission in cancer research, cure, and education. 

Join our *Kickstarter Fundraiser*, help us reach 'one part' of our financial goal by the end of August, help us build together our CERI Cancer Research Laboratory to conduct in-house CAR-T cell immunotherapy and educate the public straight from the laboratory!

Donate today whatever amount you can and please share so that everyone can be a part of our important, life-saving mission! 

Find more on the benefits you'll receiving when you donate on our website at canceredinstitute.org/donate.  

And please, feel free to start your own fundraiser on our behalf to support us! 

Thank you!
Your CERI Family
Picture
0 Comments

Phase 2 study results for Chronic Lymphocytic Leukemia (CLL) patients

6/17/2019

0 Comments

 
Tweet
Combining venetoclax (Veneclexta) + ibrutinib (Imbruvica) may be an effective initial treatment for previously untreated patients with CLL (a.k.a Chronic Lymphoblastic Leukemia), ​results of a Phase II (Phase 2) study by The University of Texas MD Anderson Cancer Center, published on May 29, 2019, suggest.
Both of these drugs are already FDA approved. The study was conducted with 80 previously untreated patients.
  • Median age was 65 years with 30 percent over age 70.
  • Of these patients, 92% had high-risk genetic anomalies.
  • 88% of patients had complete remission with normal or incomplete blood count recovery after 12 cycles of treatment.
  • 61% of patients had complete remission with undetectable minimal residual disease.
  • 60% of patients developed low white blood cell counts, similar to what has been reported in other venetoclax combination trials.
​
According to the researchers, the combination of these two drugs gave substantially better results than each of these two drugs alone. 

The researchers also added that more robust therapies for CLL patients are needed, due to the fact that:
  1. majority of patients are older than 65, and
  2. that the existing therapies are not always effective.

One of the lead researchers, Dr. Jain, said the following: “This group of patients often has unacceptable side effects and has a lower rate of complete remission and undetectable minimal residual disease. Our data showed that non-chemotherapy, combination therapy with ibrutinib and venetoclax demonstrated no new toxic effects compared to what has been previously reported for the individual agents.”

No new safety concerns were observed with the combination therapy.

The current median follow-up of the trial is 14.8 months. However, according to the researchers a longer follow-up is needed to adequately assess the long-term safety of this combination.

Study findings were published in New England Journal of Medicine on May 29, 2019.

Lead researchers of the study included:
  • Nitin Jain, M.D., Associate Professor of Leukemia 
  • William Wierda, M.D., Ph.D., Professor of Leukemia
  • Varsha Gandhi, Ph.D., Department Chair ad interim of Experimental Therapeutics
Phase II study results for Chronic Lymphocytic Leukemia (CLL) patients - Cancer Education and Research Institute (CERI)
References: 
  1. ​Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients. 
  2. Ibrutinib and Venetoclax for First-Line Treatment of CLL, Nitin Jain, M.D., Michael Keating, M.D., Philip Thompson, M.D., et al., N Engl J Med 2019; 380:2095-2103.

#ChronicLymphocyticLeukemia #CLL #ChronicLymphoblasticLeukemia #clinicaltrials #mdanderson #mdandersoncancercenter #leukemia #cancertreatment #venetoclax #Veneclexta #ibrutinib #Imbruvica
0 Comments

​May is Melanoma and Skin Cancer Awareness Month

5/11/2019

0 Comments

 
​May is Melanoma and Skin Cancer Awareness Month! We have much information on skin cancer, melanoma (the most serious and dangerous type of skin cancer), sunscreens, tanning beds and melanoma risk, sun protection, and much more on our website (simply select any of our articles you'd like to read from the list) and on our Youtube channel. 
​
#MelanomaAwarenessMonth #SkinCancerAwarenessMonth 
Melanoma and Skin Cancer Awareness Month - Cancer Education and Research Institute (CERI)
​#may #skincancer #melanoma #tanningbed #solarium #cancer #cancerawareness #cancerprevention #cancereducation #cancerpatients #cancersurvivors #sunscreens #sunblock #sunprotection #health #healthylifestyle
0 Comments

May is Brain Cancer Awareness Month

5/11/2019

0 Comments

 
May is Brain Cancer Awareness Month! We have much information on brain cancer, including glioblastoma multiforme (GBM), the most aggressive and deadly type of brain cancer in adults, FDA approvals, news, wireless phones and much more on our website. Simply select any of our articles you'd like to read. 

Also, don't forget to get our handmade CERI Brain Cancer Awareness Scarf, in memory or in honor of your loved ones, or simply show support to our cancer programs. We have only 2 items left - so, get your scarf today on our online store.  

#canceredinstitute 
Brain Cancer Awareness Month - Cancer Education and Research Institute (CERI)
#BrainCancerAwarenessMonth #may #braincancer #glioblastoma #glioblastomamultiforme #GBM #neuroblastoma #childhoodbraincancer #adultbraincancer #cancerresearch #fdaapprovals #cancerdrugs #cancertreatment #cancerawareness #cancereducation #cancerpatients #cancersurvivors #childhoodcancer
0 Comments

National Women's Check-Up Day

5/11/2019

0 Comments

 
May 9 is National Women's Check-Up Day! We have much information on breast, cervical, and ovarian cancers as well as on thermography on our website at canceredinstitute.org and on our youtube channel at youtube.com/canceredinstitute. 
Doing your regular check-ups is very important not only for early detection of cancer, but also for 'any' disease. 
_____

Don't forget to follow us @canceredinstitute #canceredinstitute 
and subscribe to our youtube channel, don't miss our cancer videos: youtube.com/canceredinstiute 
National Women's Check-Up Day - Cancer Education and Research Institute (CERI)
#nationalwomenscheckupday #may #cancerawareness #womenshealth #checkup #health #checkupday #breastcancer #cancer #ovariancancer #cervicalcancer #thermography #ultrasound #mammogram #earlydetection #earlydetectionofcancer #cancerdiagnosis #earlydiagnosis
0 Comments

BREAKING NEWS-Gene identified necessary for pancreatic cancer development

5/3/2019

0 Comments

 
Gene identified necessary for pancreatic cancer development!
Researchers from New York University and University of Michigan have identified a gene called Atdc (ataxia-telangiectasiagroup D-complementing) that is necessary for pancreatic cancer development. 

Pancreatic ductaladenocarcinoma (PDA) is an aggressive form of pancreatic cancer that is driven by the oncogenic (cancer causing) KRAS. It is diagnosed in late stages and is resistant to therapy. 

“We thought the deletion [
of the Atdc gene] would slow cancer growth, not completely prevent it,” said Diane Simeone, director of the Pancreatic Cancer Center of NYU LangoneHealth’s PerlmutterCancer Center, and corresponding author of the study. 
BREAKING NEWS-Gene identified necessary for pancreatic cancer development - Cancer Education and Research Institute (CERI)
The researchers have shown that deletion of the ataxia-telangiectasia group D-complementing (Atdc) gene, which is up-regulated (found in multiple copies) in the majority of pancreatic adenocarcinoma, completely prevented PDA development in the context of oncogenic KRAS. When the Atdc gene was present, 100% of the mice with KRAS and other mutations (gene abnormalities) developed PDA.  Mice lacking ATDC are protected from developing PDA.

As for the mechanism, the researchers showed that ATDC promotes acinar–ductal metaplasia (ADM) to pancreatic intraepithelial neoplasia (PanIN) through the activation of β-catenin signaling and subsequent SOX9 up-regulation (over expression). 

This breakthrough study revealed great hope for the development of potential new therapies for pancreatic cancer. 
The study has been published today, May 2, 2019 in the scientific journal Genes & Development.

Corresponding author of this study is Dr. Diane Simeone: diane.simeone@nyulangone.org

#breakingnews #breakthrough #science #sciencenews #cancerresearch #pancreaticcancer #cancer #cancerresearch #genes #newyorkuni #nyulangone #umich #umichigan #newyork #michigan #langone #hope #pancreaticcancerawareness
0 Comments

Drinking when young increases breast cancer risk study reports

10/3/2018

0 Comments

 
Tweet
Young women who regularly drink alcohol before their first pregnancy may be increasing their risk for breast cancer study published in The Journal of the National Cancer Institute reports. The study says that the "breast tissue is particularly susceptible to carcinogens between menarche and first full-term pregnancy". 

This report is the conclusion of a 20-year study, summerizing data from 91,005 parous women. 

The report concludes that "Alcohol consumption before first pregnancy was consistently associated with increased risks of proliferative benign breast disease (BBD) and breast cancer."

Drinking when young increases breast cancer risk - cancer education and research institute
References: 
  1. J Natl Cancer Inst;2013;105:1571–1578
  2. The New York Times, 9/6/2013. 
#breastcancer #driking #womendrinking #breastcancerrisk #cancerrisk #drinkingandcancerrisk #drinkingandbreastcancerrisk #alcohol #effectsofalcohol #health #cancer #breastcancerawareness #cancerawreness #breastcancerawarenessmonth #BCAM #cancerprevention #cancereducation #canceredinstitute 
0 Comments

Today is World Cancer Day!

2/4/2017

0 Comments

 
Today is World Cancer Day! Help us to raise awareness for Cancer and the importance of cancer education - become a CERI Golden Hearts member today!
http://www.canceredinstitute.org/membership.html
World Cancer Day - Cancer Education and Research Institute (CERI)
#WorldCancerDay #Cancer #patienteducation #publiceducation #cancereducation #cancerawareness #canceredinstitute
0 Comments

Engineered “shared” immune cells led to remission in childhood leukemia

1/28/2017

0 Comments

 
Tweet
Picture
Read the scientific article entitled Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells here.

To learn more about Acute Lymphoblastic Leukemia (ALL), read our article here.   

​#leukemia #ALL #AcuteLymphoblasticLeukemia #CAR #CARTCells #immunesystem #geneengineering #TALEN #Crispr #geneediting #universalTcells #universalimmunecells #childhoodleukemia #cchildhoodcancer #universitycollegelondon #cancerresearch #cancertreatment #cancer #cancereducation #patientenducation #publiceducation #canceredintitute 
0 Comments

Capsaicin in chillies kills breast cancer cells

1/3/2017

0 Comments

 
Tweet
Capsaicin in chillies kills breast cancer cells - Cancer Education and Research Institute (CERI)
Researchers from Ruhr-University in Bochum, Germany, treated human samples of breast cancer cells with Capsaicin to dissect its ability to destroy them. They found that Capsaicin induces apoptosis (cell death) in cancer cells. When capsaicin reaches a cancer cell, it attaches to the cell surface and switches on a cell receptor, a protein expressed/produced on the cell surface, called TRPV1. The receptor TRPV1 is a calcium/sodium channel that controls them go in and out of the cancer cell. When TRPV1 is switched on by capsaicin, the cancer cell is sent into overdrive and starts to self-destruct by induced apoptosis (programmed cell death). The researchers have found a significant reduction in cell proliferation after capsaicin stimulation was observed.This study was carried out by scientists from:
  • Ruhr-University in Bochum, Germany
  • Hospital Herz-Jesu-Krankenhaus Dernbach, Germany
  • Centre of Genomics in Cologne, Germany

Read more here in the news, and the original scientific article, Expression and functionality of TRPV1 in breast cancer cells, here.


0 Comments
<<Previous

    Archives

    September 2019
    June 2019
    May 2019
    October 2018
    February 2017
    January 2017
    December 2016
    November 2016
    September 2016
    June 2016
    May 2016
    April 2016
    March 2016
    January 2016
    December 2015
    November 2015
    October 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013

    Categories

    All
    Cancer News
    Cancer News
    Cancer Research Simplified News
    Crs News
    Crs News
    Holidays
    Quotes

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-proft organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe

Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2019 Cancer Education and Research Institute®. All Rights Reserved.                                  
Powered by Cancer Education and Research Institute®
Picture